Study of the technological properties of excipients in the development of the composition of orally dispersible tablets

Introduction. The article presents the results of studying the technological properties of individual excipients widely used in the compositions of existing orally dispersed tablets (ODT) for subsequent planning a multifactorial experiment. Samples of excipients were analyzed according to such pharmacopoeial indicators as description, flowability, bulk density, compressibility, fractional composition, solubility in water.

Aim. The aim of the work is to create a list and study the technological properties of candidate substances for the role of auxiliary substances in the composition being developed by the ODT.

Materials and methods. The technological properties of excipient samples were studied according to the methods of the State Pharmacopoeia of the XIV edition using the flowability tester GTL (ERWEKA, Germany), the bulk density tester SVM 221 (ERWEKA, Germany), the tablet press PGR-10 (LabTools, Russia) and the tablet hardness tester TBH 125 TDP (ERWEKA, Germany).

Results and discussion. As a result of the study, experimental data on the technological properties of excipient samples were collected, and the selected samples were compared according to pharmaceutical and technological indicators.

Conclusion. In the course of the study, a list of auxiliary substances for the development of the composition of ODT was formed and studies of their technological properties were carried out. The obtained experimental data will allow to develop an optimal matrix of a multifactorial experiment for the development of the composition of ODT and justify the choice of excipients.

1. Şenel S., Comoglu T. Orally disintegrating tablets, fast-dissolving, buccal and sublingual formulations. Pharmaceutical Development and Technology. 2018;23(5):431. DOI: 10.1080/10837450.2018.1462471.

2. van der Merwe J., Steenekamp J., Steyn D., Hamman J. The Role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics. 2020;12(5):393. DOI: 10.3390/pharmaceutics12050393.

3. Lin Z., Xuan J. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China. Expert Review of Pharmacoeconomics & Outcomes Research. 2020;20(5):549–557. DOI: 10.1080/14737167.2020.1807331.

4. Mahrous G. M., Ibrahim M. A., Mostafa H. F., Elzayat E. M. Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-masking agent in dextromethorphan hydrobromide orally disintegrating tablets. Pharmaceutical Development and Technology. 2019;24(6):711–719. DOI: 10.1080/10837450.2019.1579228.

5. Comoglu T., Dilek Ozyilmaz E. Orally disintegrating tablets and orally disintegrating mini tablets – novel dosage forms for pediatric use. Pharmaceutical Development and Technology. 2019;24(7):902–914. DOI: 10.1080/10837450.2019.1615090.

6. ICH Q8 Pharmaceutical development. Available at: http://www.ich. org. Accessed: 17.05.2021

7. Gulsun T., Akdag Y., Izat N., Cetin M., Oner L., Sahin S. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets. Pharmaceutical Development and Technology. 2020;25(8):999–1009. DOI: 10.1080/10837450.2020.1772290.

8. Yu J., Shan X., Chen S., Sun X., Song P., Zhao R., Hu L. Preparation and evaluation of novel multi-channel orally disintegrating tablets. European Journal of Pharmaceutical Sciences. 2020;142:105108. DOI: 10.1016/j.ejps.2019.105108.

9. Vanbillemont B., Everaert H., De Beer T. New advances in the characterization of lyophilised orally disintegrating tablets. International Journal of Pharmaceutics. 2020;579:119153. DOI: 10.1016/j.ijpharm.2020.119153.

10. Sharma S., Singh K. Oral Disintegrating tablets – an updated patent perspective. Recent patents on drug delivery & formulation. 2020;14(3):166–190. DOI: 10.2174/1872211314999201123202930.

11. Bowles B. J., Dziemidowicz K., Lopez F. L., Orlu M., Tuleu C., Edwards A. J., Ernest T. B. Co-processed excipients for dispersible tablets-part 1: manufacturability. AAPS PharmSciTech. 2018;19(6):2598–2609. DOI: 10.1208/s12249-018-1090-4.